Patents Assigned to Wyeth
  • Method of purifying moxidectin through crystallization
    Patent number: 7645863
    Abstract: Methods for the purification of the macrolide moxidectin result in higher purity levels than can often otherwise be obtained. The crystalline moxidectin is then used in a wide variety of pharmaceutical and veterinary applications, including the prevention, treatment and control of parasites in plants, animals and humans.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: January 12, 2010
    Assignee: Wyeth LLC
    Inventors: Isidoro H. Sorokin, Paola Di Raimondo, Chin-Liang Chou
  • Indoline derivatives
    Patent number: 7645761
    Abstract: This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: wherein R1 and R2 may be single substituents or fused to form spirocyclic rings.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: January 12, 2010
    Assignee: Wyeth
    Inventors: Andrew Fensome, Lori L. Miller, John W. Ullrich, Reinhold H. W. Bender, Puwen Zhang, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
  • (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
    Publication number: 20100003250
    Abstract: The invention relates to 2-aryl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Application
    Filed: July 2, 2009
    Publication date: January 7, 2010
    Applicant: Wyeth
    Inventors: Zecheng Chen, Aranapakam Mudumbai Venkatesan, Arie Zask, Jeroen Cunera Verheijen, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Kevin Joseph Curran
  • Methods for monitoring drug activities in vivo
    Patent number: 7643943
    Abstract: Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulatable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: January 5, 2010
    Assignee: Wyeth LLC
    Inventors: Michael E. Burczynski, Joseph Boni, Andrew J. Dorner, Natalie C. Twine, Jennifer Stover, William L. Trepicchio, Virginia Fitzpatrick, Fred Immermann
  • Recombinant lubricin molecules and uses thereof
    Patent number: 7642236
    Abstract: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura are provided.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: January 5, 2010
    Assignee: Wyeth
    Inventors: Carl Ralph Flannery, Christopher John Corcoran, Bethany Annis Freeman, Lisa A. Collins-Racie
  • DUAL ADHESIVE TECHNOLOGY
    Publication number: 20090324714
    Abstract: A dual adhesive layer dosage form for delivery of active agent to and across, the mucosa is disclosed. Particularly, bioadhesive tablets for administration at the vaginal mucosa are disclosed as having a central active layer sandwiched between two bioadhesive layers.
    Type: Application
    Filed: June 26, 2009
    Publication date: December 31, 2009
    Applicant: WYETH
    Inventors: Xiuying LIU, John KRESEVIC
  • 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS
    Publication number: 20090325916
    Abstract: Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.
    Type: Application
    Filed: September 2, 2009
    Publication date: December 31, 2009
    Applicant: Wyeth
    Inventors: Puwen Zhang, Jeffrey Curtis Kern, Eugene Anthony Terefenko, Eugene John Trybulski
  • LYOPHILIZATION CYCLE ROBUSTNESS STRATEGY
    Publication number: 20090324586
    Abstract: The present invention provides methods for assessing and optimizing lyophilization cycle robustness. In particular, the present invention provides rapid assessment of cycle robustness with respect to a variety of lyophilization process deviations by varying a relatively small number of parameters.
    Type: Application
    Filed: June 25, 2009
    Publication date: December 31, 2009
    Applicant: Wyeth
    Inventors: Serguei Tchessalov, Daniel Dixon, Anthony Barry, Nicholas Warne
  • THIAZOLO NAPHTHYL ACIDS
    Publication number: 20090326021
    Abstract: The present invention relates to thiazolo-naphthyl acids of the formula and methods of using them to modulate PAI-1 expression and to treat PAI-1 related disorders.
    Type: Application
    Filed: September 4, 2009
    Publication date: December 31, 2009
    Applicant: Wyeth
    Inventor: Thomas J. COMMONS
  • METHODs OF DETECTION AND QUANTIFICATION OF HOST CELL DNA CONTAMINATION OF PURIFIED PROTEINS
    Publication number: 20090325175
    Abstract: The present invention provides a novel robust, sensitive, reproducible, and accurate method of detecting and quantifying host cell genomic DNA contamination utilizing quantitative real time Polymerase Chain Reaction (qPCR), wherein the qPCR primers are complementary to the highly repetitive host cell genomic DNA sequences, e.g., Alu-equivalent sequences. The present invention is particularly useful for determining the levels of residual genomic DNA in biological products to be administered as therapeutics, e.g., therapeutic proteins.
    Type: Application
    Filed: June 1, 2009
    Publication date: December 31, 2009
    Applicant: WYETH
    Inventors: Karin Anderson, Mark William Leonard, Denise Alice Fahey
  • Gene Expression Profiles Associated with Asthma Exacerbation Attacks
    Publication number: 20090325176
    Abstract: The present invention provides methods for the assessment, diagnosis, or prognosis of asthma exacerbation, by assessing the level of expression of asthma exacerbation gene products in a sample derived from a patient. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma.
    Type: Application
    Filed: June 5, 2009
    Publication date: December 31, 2009
    Applicant: Wyeth
    Inventors: Margot Mary O'Toole, Frederick William Immermann, Padmalatha Sunkara Reddy, Andrew Arthur Hill, John Louis Ryan, Andrew Joseph Dorner, Cristina Ileana Csimma, Charlotte Marie McKee, Wei Liu, Divya Chaudhary, Matthew Ren Silver
  • Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer
    Publication number: 20090325877
    Abstract: A pharmaceutical combination product is disclosed that comprises a receptor tyrosine kinase inhibitor and a fatty acid synthase inhibitor, and to the use thereof in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
    Type: Application
    Filed: May 22, 2009
    Publication date: December 31, 2009
    Applicant: Wyeth
    Inventors: Thomas Grunt, Renate Wagner
  • ENANTIOMERS OF O-DESMETHYL VENLAFAXINE
    Publication number: 20090326075
    Abstract: This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(?)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(?)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central nervous system disorders.
    Type: Application
    Filed: September 4, 2009
    Publication date: December 31, 2009
    Applicant: Wyeth
    Inventors: John P. Yardley, Andrew A. Asselin
  • Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
    Publication number: 20090325964
    Abstract: The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I: wherein the constituent variables are as defined herein. The present teachings further relate to methods for the preparation of the compounds, and to methods for using the compounds for treatment of diseases and disorders including schizophrenia, paranoia, depression, manic-depressive illness and anxiety.
    Type: Application
    Filed: May 22, 2009
    Publication date: December 31, 2009
    Applicant: Wyeth
    Inventors: Matthew Gregory Bursavich, Adam Matthew Gilbert, Joseph Raymond Stock
  • Peptides as solubilizing excipients for transforming growth factor ? proteins
    Patent number: 7638495
    Abstract: The present invention relates to compositions comprising excipients or solubilizing agents for proteins. The invention relates to the discovery that a peptide derived from the N-terminus extension of the T266 isoform of rhBMP-2 has properties that enhance the solubility of proteins. The invention also relates to methods of resolubilizing a protein that has precipitated, by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2. The invention also relates to methods of increasing the solubility of a protein by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: December 29, 2009
    Assignee: Wyeth
    Inventors: Pilarin Elizabeth Louise Nichols, Bernardo Perez-Ramirez
  • Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases
    Patent number: 7638482
    Abstract: The present invention is based on the discovery that ?PKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ?PKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ?PKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: December 29, 2009
    Assignee: Wyeth
    Inventors: Edward R. LaVallie, Lisa A. Collins-Racie, Maya Arai
  • Phenylaminopropanol derivatives and methods of their use
    Patent number: 7638512
    Abstract: The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
    Type: Grant
    Filed: June 23, 2008
    Date of Patent: December 29, 2009
    Assignee: Wyeth
    Inventors: An Thien Vu, Paige Erin Mahaney, Stephen Todd Cohn
  • 1-SUBSTITUTED-3-(NAPHTHALEN-1-YLSULFONYL)-5-(PIPERAZIN-1-YL)-1H-INDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
    Publication number: 20090318470
    Abstract: The disclosure is directed to compounds of Formula I: processes for their preparation, treatment of central nervous system (CNS) disorders and methods for the modulation of 5HT6 activity.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 24, 2009
    Applicant: Wyeth
    Inventors: Kevin Guangcheng Liu, Albert Jean Robichaud, Jennifer Rebecca Lo
  • THIAZOLYL-AND OXAZOLYL-ISOQUINOLINONES AND METHODS FOR USING THEM
    Publication number: 20090318442
    Abstract: The present invention relates to substituted thiazolyl- and oxazoyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thiazolyl- and oxazolyl-isoquinolinones and to their use in treating various diseases and disorders.
    Type: Application
    Filed: June 18, 2009
    Publication date: December 24, 2009
    Applicant: Wyeth
    Inventors: Roberto PELLICCIARI, Flavio Moroni, Adam Matthew Gilbert
  • COMPOSITIONS AND METHODS OF USE OF ORF 554 FROM BETA HEMOLYTIC STREPTOCOCCAL STRAINS
    Publication number: 20090318358
    Abstract: The present invention relates to compositions and methods of use comprising peptidyl-prolyl isomerase (PPI) polypeptides of group C and G streptococci and polynucleotides encoding same. The invention also relates to immunogenic compositions comprising the PPI polypeptides and polynucleotides, as well as antibodies and antibody fragments that bind the PPI polypeptides. In addition, the invention relates to methods of inducing an immune response in a subject against beta hemolytic streptococci using the immunogenic compositions, as well as conferring passive immunity by administering a therapeutic antibody or antibody fragment.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 24, 2009
    Applicant: Wyeth
    Inventors: Ellen Murphy, Emily Mara Braunstein, Dorys Garcia-Hand, Annaliesa Sybil Anderson, Ingrid Lea Dodge, Eduardo Arturo Rojas